Dai Gao

Dai Gao

Auto-generated profile, based on publicly available information

Dai Gao

Department of Rheumatology and Clinical immunology, Peking University First Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
YFYong Fan
Yong Fan
YGYan Geng
Yan Geng
YWYu Wang
Yu Wang
XDXuerong Deng
Xuerong Deng
GLGuangtao Li
Guangtao Li
ZZZhuoli Zhang
Zhuoli Zhang

1 December 2020 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
YWYiwen Wang
Yiwen Wang
ZZZheng Zhao
Zheng Zhao
DGDai Gao
Dai Gao
HWHui Wang
Hui Wang
SLSimin Liao
Simin Liao
FHFeng Huang
Feng Huang

12 April 2022 in Rheumatology
Verified
Journal Article
Closed access
PDF file
LJLanlan Ji
Lanlan Ji
DGDai Gao
Dai Gao
YHYanjie Hao
Yanjie Hao
HHHong Huang
Hong Huang
YWYu Wang
Yu Wang
ZZZhuoli Zhang
Zhuoli Zhang
To assess the risk of flare in systemic lupus erythematosus (SLE) patients after low dose glucocorticoids (GC) discontinuation and evaluate the risk factors of flare. SLE patients who ever discontinued GC were identified from PKUFHS cohort. The disease flare profile after GC discontinuation were analyzed. Flare rate was analyzed using Kaplan-Meier analysis. Cox regression was used to determine the effect of variables on SLE flare. A prognostic nomogram using Cox proportional hazards regression modeling were developed. 132 SLE patients were eligible for the final analysis. They were followed up for a median (IQR) period of 21.8 (9.01, 36.7) months. The cumulative probability of flare after GC discontinuation was 8.3% at 6 months, 16.8% at year 1 and 27.5% at year 2. In multivariate Cox analysis, hypocomplementemia and serologically active clinically quiescent (SACQ) were independent risk factors of flare [HR 2.53, 95% CI (1.32, 4.88); HR 3.17, 95% CI (1.44, 6.97), respectively]. Age ≥ 40 y at GC withdrawal and hydroxychloroquine usage were independent protective factors of flare [HR 0.53, 95% CI (0.29, 0.99); HR 0.32, 95% CI (0.17, 0.62), respectively]. The protective effect of hydroxychloroquine was dosage related. From the prospective of different tapering strategies embodied as duration from prednisone 5 mg/d to complete discontinuation, slower tapering strategy (12–24 months) significantly reduced the risk of flare compared with faster tapering strategy (< 3 months) [HR 0.30, 95% CI (0.11, 0.82), p= 0.019]. The prognostic nomogram including aforementioned factors effectively predicted 1- and 2-year probability of flare-free. Low-dose GC is feasibly discontinued in real-life setting. SACQ and younger age are potential risk factors of SLE flare, while hydroxychloroquine usage and slow GC tapering to withdrawal can reduce relapse. The visualized model we developed may help to predict risk of flare among SLE patients who discontinued GC.

1 February 2018 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
YWYiwen Wang
Yiwen Wang
ZGZhiwei Guan
Zhiwei Guan
DGDai Gao
Dai Gao
GLGui Luo
Gui Luo
KLKunpeng Li
Kunpeng Li
FHFeng Huang
Feng Huang

26 April 2020 in Rheumatology
Verified
Journal Article
Open access
PDF file
DGDai Gao
Dai Gao
YHYanjie Hao
Yanjie Hao
LMLin Mu
Lin Mu
WXWenhui Xie
Wenhui Xie
YFYong Fan
Yong Fan
ZZZhuoli Zhang
Zhuoli Zhang
Objectives: To evaluate the attainability of Lupus Low Disease Activity State (LLDAS) and definitions of remission in SLE (DORIS) in a treatment-naïve cohort of SLE. Methods: LLDAS5 was defined as LLDAS with a prednisone dose ≤5 mg/day. There were four definitions in DORIS: clinical remission on treatment (RONT), complete RONT, clinical remission off treatment (ROFT) and complete ROFT. The treatment-naïve patients from Peking University First Hospital SLE cohort were enrolled. The time to each state and their annual cumulative probabilities were estimated. The frequencies of patients who achieved each component of LLDAS or DORIS during follow-up were determined. The predictors of time to each state were identified. Results: A total of 218 patients were included, with a median follow-up of 4.48 years. Respectively, 190 (87.2%), 160 (73.4%), 148 (67.9%), 94 (43.1%), 23 (10.6%) and 18 (8.3%) patients achieved LLDAS, LLDAS5, clinical RONT, complete RONT, clinical ROFT and complete ROFT. The median time to LLDAS, LLDAS5, clinical RONT and complete RONT were 1.4, 2.3, 2.6 and 4.7 years, respectively. Positive anti-dsDNA, RP and anaemia were significantly associated with prolonged time to LLDAS, LLDAS5 or clinical RONT. Conclusion: Our data confirmed that LLDAS is an attainable early treatment target for SLE. Though with more difficulty, RONT can be achieved in two-thirds of our patients. ROFT may not be an ideal treatment target at present as it is only attained in few patients.

4 June 2017 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
YWYiwen Wang
Yiwen Wang
KLKunpeng Li
Kunpeng Li
DGDai Gao
Dai Gao
GLGui Luo
Gui Luo
YZYurong Zhao
Yurong Zhao
FHFeng Huang
Feng Huang